Sunday, March 16, 2025
HomeNews

News

Trodelvy Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer

Gilead Sciences, Inc. announced new and updated positive results from three cohorts of the Phase 2 TROPHY-U-01 study of Trodelvy for the treatment of...

Adjuvant Opdivo (nivolumab) Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years in CheckMate...

Bristol Myers Squibb announced three-year follow-up results from the Phase 3 CheckMate -274 trial, demonstrating significant sustained clinical benefits with Opdivo (nivolumab) for the adjuvant...

Breakthrough Discoveries in Human Immunology – Michelson Philanthropies and AAAS/Science Award Transformative Research

Michelson Philanthropies and AAAS/Science award Dr. Aleksandar Obradovic,of the Department of Systems Biology at Columbia University Irving Medical Center, with the 2023 Michelson Philanthropies & Science Prize for Immunology....

SparkFun Electronics, InPlay, and Bosch Sensortec partner to release two new NanoBeacon boards to accelerate development of wireless IoT solutions

In collaboration with InPlay and Bosch Sensortec, SparkFun is pleased to release two new IoT development boards: the SparkFun NanoBeacon Board - IN100  and...

Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA...

Ligand Pharmaceuticals Incorporated announced that its partner Travere Therapeutics, Inc.  has received accelerated approval from the U.S. Food and Drug Administration for FILSPARI to...
0FansLike
0FollowersFollow
spot_img

Hot Topics